Pharmacologic therapy of lipid disorders in the elderly

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Preventive Cardiology

Background:

• Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality in older adults.
• Elevated low-density lipoprotein (LDL) cholesterol is a primary modifiable risk factor for ASCVD.
• Current guidelines recommend lipid-lowering therapies for specific patient populations at high risk.

Purpose of the Study:

• To outline evidence-based recommendations for lipid-lowering drug therapy in older adults.
• To define target LDL cholesterol levels for patients with established ASCVD and those at high risk.
• To provide guidance on the selection and combination of lipid-lowering agents.

Main Methods:

• Review of clinical guidelines and landmark studies on lipid management.
• Analysis of treatment strategies for hyperlipidemia in older populations.
• Consideration of drug efficacy and safety profiles, including statins, bile acid binding resins, and gemfibrozil.

Main Results:

• Lipid-lowering drug therapy, preferably statins, is recommended for older adults with established ASCVD and LDL cholesterol > 125 mg/dL, aiming for LDL < 100 mg/dL.
• In cases where statins alone do not achieve LDL goals, adding a bile acid binding resin is advised due to a lack of increased myositis risk.
• Statins are also indicated for older adults without ASCVD but with significant risk factors (e.g., LDL > 160 mg/dL with one risk factor, or LDL 130-159 mg/dL with low HDL).
• Gemfibrozil may benefit patients with coronary artery disease and low HDL cholesterol.
• No strong evidence supports treating isolated hypertriglyceridemia for cardiovascular disease prevention.

Conclusions:

• Aggressive LDL cholesterol reduction with statins is crucial for older adults with established ASCVD.
• Combination therapy with bile acid binding resins can be a safe and effective strategy when statins are insufficient.
• Lipid management should be tailored based on ASCVD risk factors, LDL levels, and HDL cholesterol levels.
• Further research is needed for isolated hypertriglyceridemia management.